Cabaletta (CABA, Financial) recently received a reaffirmed Buy rating from H.C. Wainwright, along with a $25 price target set by analyst Douglas Tsao. This optimism stems from "promising" early efficacy and safety outcomes in trials related to myositis, lupus, and scleroderma, reinforcing the company's leadership in cell therapy for autoimmune conditions.
At the EULAR 2025 conference, Cabaletta shared impressive results involving 18 patients who received rese-cel treatment across the REST-Myositis, -SLE, and -SSc studies. Notably, seven out of eight myositis patients responded clinically without the use of immunomodulators and were either off or reducing steroid use. Similarly, all seven lupus (SLE) patients showed clinical improvement without relying on immunomodulators or glucocorticoids.
